Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 6/2004

01-06-2004 | Case Report

Remission induced by Campath-1H for thymoma-associated agranulocytosis

Authors: C. L. Alvares, D. Svasti-Salee, M. Rowley, E. C. Gordon-Smith, J. C. W. Marsh

Published in: Annals of Hematology | Issue 6/2004

Login to get access

Abstract

Thymoma-associated agranulocytosis is a rare but almost universally fatal condition. Reports to date have described several immunosuppressive therapies including steroids, cyclophosphamide and vincristine as adjuvants to thymectomy, in an effort to improve neutropenia. We report the response to the monoclonal antibody Campath-1H of a patient with a thymoma and associated agranulocytosis with complete absence of bone marrow granulocyte precursors, which had failed to respond to thymectomy. Treatment with Campath-1H resulted in complete responses of promising durability sustained with the addition of cyclosporin and mycophenolate mofetil as maintenance therapy.
Literature
1.
Calne R, Friend P, Moflatt S, Bradley A, Hale G, Firth J, Bradley J, Smith K, Waldmann H (1998) Prope tolerance peri-operative Campath-1H, and low dose cyclosporin monotherapy in renal allograft recipients. Lancet 352:408PubMed
2.
Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chaterjee V, Waldmann H, Compston A (1999) Pulse monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354:1691–1695CrossRefPubMed
3.
Hale G, Waldmann H (1996) Recent studies using Campath-1H antibodies to control GvHD and graft rejection. Bone Marrow Transplant 17:305–308PubMed
4.
Isaacs JD, Watts RA, Hazelman BL, Hale G, Keogan MT, Cobbold SP, Wadmann H (1992) Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:748–752CrossRefPubMed
5.
Killick SB, Marsh JCW, Hale G, Waldmann H, Kelly SJ, Gordon-Smith EC (1997) Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br J Haematol 97:306–308CrossRefPubMed
6.
Marsh JCW, Gordon-Smith EC (2001) Campath-1H in the treatment of autoimmune cytopenias. Cytotherapy 3:189–195CrossRefPubMed
7.
Nagvekar N, Moody A, Moss P, Roxanis I, Curnow J, Beeson D, Pantic N, Newsom-Davis J, Vincent A, Wilcox N (1998) A pathogenetic role for the thymoma in myasthenia gravis. J Clin Invest 101:2268–2277PubMed
8.
Reichman L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323–327PubMed
9.
Weir AB, Dow LW (1989) Response of agranulocytosis to thymectomy in a patient with thymoma and CLL. Med Paediatr Oncol 17:58–61
10.
Wilcox NM, Schleup MA, Ritter HJ, Schuuman J, Newsom-Davis J, Christensson B (1987) Myasthenic and non-myasthenic thymoma. An expansion of minor cortical epithelial cell subsets? Am J Pathol 127:447–460PubMed
11.
12.
Willis F, Marsh JCW, Bevan D, Killick S, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC (2001) The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 114:891–898CrossRefPubMed
13.
Yip D, Rasko JEJ, Lee C, Kronenberg H, O’Neill B (1996) Thymoma and agranulocytosis: two case reports and literature review. Br J Haematol 95:52–56CrossRefPubMed
Metadata
Title
Remission induced by Campath-1H for thymoma-associated agranulocytosis
Authors
C. L. Alvares
D. Svasti-Salee
M. Rowley
E. C. Gordon-Smith
J. C. W. Marsh
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 6/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0834-7

Other articles of this Issue 6/2004

Annals of Hematology 6/2004 Go to the issue

Case Report

Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT)

Original Article

Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: results of a prospective multicenter trial

Case Report

CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

Case Report

Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient

Case Report

Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B

Original Article

Acute myeloid/NK precursor cell leukemia with trisomy 4 and a novel point mutation in the extracellular domain of the G-CSF receptor in a patient with chronic idiopathic neutropenia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits